Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting

THOMSON REUTERS12-06 21:00

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589082599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-06 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589082599","market":"nz","top_or_hot":-1,"title":"Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting","media":"THOMSON REUTERS","content":"<html><body><p>Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting</p></body></html>","source":"reuters_en_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-06 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nTUA4MJXRZ:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nTUA4MJXRZ:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nTUA4MJXRZ:1","article_id":"2589082599","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589082599","pubTimestamp":1765026000,"columns":[],"sourceInfo":{"source_id":"reuters_en_live","name":"Thomson Reuters"},"weMediaInfo":null,"summary":"Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Ris","collect":0,"end_time":0,"defaultTopTitle":"refinitiv.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4535":"淡马锡持仓","BK4505":"高瓴资本持仓","BK4611":"AI医疗","BK4139":"生物科技","BEAM":"Beam Therapeutics, Inc."},"translate_title":"Beam Therapeutics在美国血液学会(Ash)年会上报告了Ristoglogene Autogetemcel(Risto-Cel)BEACON 1/2期试验的最新数据，强调了镰状细胞病(Scd)的持久、差异化特征","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":0.9},"content_text":"Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589082599","isCrawlerRequest":true}